London-based Causaly, a groundbreaking AI and machine learning platform, has successfully raised $60 million in a Series B funding round led by Iconiq Growth. With its ability to rapidly piece together preclinical discoveries, Causaly is poised to reshape the landscape of biomedical research. This significant investment will fuel the company's expansion of commercial relationships and solidify its position in the market, revolutionizing how scientists unravel the complexities of disease biology.
In the fast-paced world of biomedical research, Causaly stands out as a game-changer. Founded in 2018 by Artur Saudabayev and Yiannis Kiachopoulos, this London-based AI and machine learning platform empowers scientists by effortlessly sifting through vast amounts of scientific literature, regulatory documents, clinical trials, and proprietary research. With remarkable speed, Causaly brings together all the critical pieces of preclinical discovery, providing researchers with a comprehensive understanding of the underlying biology of diseases.
The recent Series B funding round, led by Iconiq Growth, marks a significant milestone for Causaly, as it secured a remarkable $60 million investment.This significant financial support will fuel the company's growth, strengthening its leadership position in the industry. The funding round garnered participation from industry giants like Index Ventures, Marathon Venture Capital, Pentech Ventures, EBRD, as well as visionary individuals like Alex Gorsky, former Chairman and CEO of Johnson & Johnson, and Olivier Pomel, CEO and Co-Founder of Datadog, adding weight to Causaly's journey towards innovation and success. Causaly's extraordinary growth is evident, with a threefold increase in revenue and customer base. Its groundbreaking technology has gained traction across the pharmaceutical landscape, with 12 of the top 20 pharma companies already leveraging Causaly's platform. By streamlining and enhancing the research process, Causaly's innovative solution empowers scientists to navigate the complexities of disease biology with unparalleled efficiency and precision.
With $60 million raised in its recent Series B funding round, Causaly is poised to transform the field of biomedical discovery. Powered by cutting-edge AI and machine learning, this London-based company accelerates the research process, providing scientists with an all-encompassing understanding of disease biology. The funding will pave the way for further commercial growth and cement Causaly's market position. As 12 of the top 20 pharma companies embrace Causaly's groundbreaking technology, the future of biomedical research looks promising with new horizons waiting to be explored.
Kiachopoulos said “Recent advances in AI open completely new possibilities, and there is a great need for transparent AI systems that science leaders can trust” “Knowledge is the lifeblood of research organizations, and we are committed to our mission to make it discoverable, working with our customers to make sense of their scientific data and apply insights to enable evidence-driven decisions.”